CN102727729B - Decoction for treating eye disease - Google Patents
Decoction for treating eye disease Download PDFInfo
- Publication number
- CN102727729B CN102727729B CN2012102094199A CN201210209419A CN102727729B CN 102727729 B CN102727729 B CN 102727729B CN 2012102094199 A CN2012102094199 A CN 2012102094199A CN 201210209419 A CN201210209419 A CN 201210209419A CN 102727729 B CN102727729 B CN 102727729B
- Authority
- CN
- China
- Prior art keywords
- parts
- rhizoma
- fructus
- decoction
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a decoction for treating eye disease. The decoction is prepared from the following traditional Chinese medicinal materials of: by weight, 13.5-17 parts of abalone shell, 13.5-17 parts of cleaver herb, 8-12 parts of gentian, 8-12 parts of phellodendron, 11-13.5 parts of anemarrhena, 11-13.5 parts of rehmanniae radix, 8-12 parts of rhizoma alismatis, 8-12 parts of cortex moutan, 8-12 parts of Poria cocos, 8-12 parts of Japanese eupatorium, 8-12 parts of chrysanthemum, 8-12 parts of prunella vulgaris, 4.5-7.5 parts of rhizoma atractylodis, 8-12 parts of tribulus terrstris,8-12 parts of Broussonetia papyrifera, 8-12 parts of Cyperus Rotundus L, 8-12 parts of motherwort fruit, 8-12 parts of Vespertilio superans Thomas and 4.5-7.5 parts of licorice. In allusion to ophthalmological real evidence, the prescription provided by the invention has advantages of elaborate compatibility, strict composition, usage of traditional Chinese medicines commonly-used in clinic and low price, and is convenient and practical. It is proved through experiments that the decoction is nontoxic, has no side effect and has substantial clinical effects.
Description
Technical field
The present invention relates to the curing eye diseases field, specifically is a kind of decoction for the treatment of oculopathy.
Background technology
Development along with social science and technology, particularly along with the generation of highly sophisticated device, modern medicine to the understanding of ophthalmology also by not having to having, by thick to essence, ophthalmology has entered the stage of a high speed development, and so far, ophthalmic diseases, especially the blinding disease has developed into the third-largest threat of human health, and modern medicine is far from reaching the stage of people's satisfaction to the progress of this type of disease.
Development along with modern society, the quickening of rhythm of life and the deterioration of air quality are followed, the sickness rate of catarrhal conjunctivitis, bacterial conjunctivitis, anaphylaxis conjunctivitis rises in recent years year by year, and external oculopathy oculopathy such as catarrhal conjunctivitis, anterior uveitis, anaphylaxis conjunctivitis can cause symptoms such as conjunctival congestion redness, ophthalmic pruritus, bite.These diseases are the exogenous diseases that belong in theory of Chinese medical science more, mostly are patient's being invaded by exogenous pathogen, or invade for ailment said due to cold or exposure, on disturb key clearly, zang-fu disharmony, or be damp and hot evil upper punch presss from both sides ailment said due to cold or exposure again so that rheumatic fever three heresies are pented up, the stasis venation.Modern medicine is used eye drop local applications such as antibiotic and hormone more on these treatment of diseases, effect still can, but the life-time service side effect is bigger.
In sum, need at present a kind of action temperature of development and, untoward reaction is little, but prolonged application is and easy to use, curative effect is fast, is difficult for the new drug of the above-mentioned oculopathy for the treatment of of bounce-back.
Summary of the invention
The invention provides a kind of decoction for the treatment of oculopathy, can be used for conjunctival congestion redness, ophthalmic pruritus, bite, etc. the treatment of oculopathy, its action temperature and, untoward reaction is little, but prolonged application is and easy to use, curative effect is fast, is difficult for bounce-back, uses, carries, keeping is all very convenient.
A kind of decoction for the treatment of oculopathy, formulated by the raw material of Chinese medicine medicine of following weight parts: Concha Haliotidis 13.5-17 part, Semen Cassiae 13.5-17 part, Radix Gentianae 8-12 part, Cortex Phellodendri 8-12 part, Rhizoma Anemarrhenae 11-13.5 part, Radix Rehmanniae 11-13.5 part, Rhizoma Alismatis 8-12 part, Cortex Moutan 8-12 part, Poria 8-12 part, Herba Lycopi 8-12 part, Flos Chrysanthemi 8-12 part, Spica Prunellae 8-12 part, Rhizoma Atractylodis 4.5-7.5 part, Fructus Tribuli 8-12 part, the sub-8-12 part of Fructus Broussonetiae, Rhizoma Cyperi 8-12 part, Fructus Leonuri 8-12 part, Faeces Vespertilionis 8-12 part, Radix Glycyrrhizae 4.5-7.5 part.
The decoction of aforesaid treatment oculopathy, formulated by the raw material of Chinese medicine medicine of following weight parts: Concha Haliotidis 14-16 part, Semen Cassiae 14-16 part, Radix Gentianae 8.5-11 part, Cortex Phellodendri 8.5-11 part, Rhizoma Anemarrhenae 11.5-13 part, Radix Rehmanniae 11.5-13 part, Rhizoma Alismatis 8.5-11 part, Cortex Moutan 8.5-11 part, Poria 8.5-11 part, Herba Lycopi 8.5-11 part, Flos Chrysanthemi 8.5-11 part, Spica Prunellae 8.5-11 part, Rhizoma Atractylodis 5-7 part, Fructus Tribuli 8.5-11 part, the sub-8.5-11 part of Fructus Broussonetiae, Rhizoma Cyperi 8.5-11 part, Fructus Leonuri 8.5-11 part, Faeces Vespertilionis 8.5-11 part, Radix Glycyrrhizae 5-7 part.
The decoction of aforesaid treatment oculopathy, formulated by the raw material of Chinese medicine medicine of following weight parts: 15 parts of Concha Haliotidis, 15 parts of Semen Cassiae, 10 parts of Radix Gentianaes, 10 parts of Cortex Phellodendris, 12 parts of the Rhizoma Anemarrhenaes, 12 parts in the Radix Rehmanniae, 10 parts of Rhizoma Alismatis, 10 parts of Cortex Moutans, 10 parts in Poria, 10 parts of Herba Lycopi, 10 parts of Flos Chrysanthemis, 10 parts of Spica Prunellaes, 6 parts of Rhizoma Atractylodis, 10 parts of Fructus Tribulis, 10 parts of Fructus Broussonetiae, 10 parts of Rhizoma Cyperis, 10 parts of Fructus Leonuris, 10 parts of Faeces Vespertilioniss, 6 parts in Radix Glycyrrhizae.
Concha Haliotidis in the decoction of the present invention, Semen Cassiae, Radix Gentianae, Cortex Phellodendri, the Radix Rehmanniae can detoxify by clearing away heat-fire; The Radix Rehmanniae, Cortex Moutan, Herba Lycopi can the removing heat from blood and promoting blood circulation blood stasis dispellings; Fructus Leonuri, Faeces Vespertilionis, Spica Prunellae, Fructus Lycii, Flos Chrysanthemi can liver and kidney tonifying, liver heat removing and eyesight improving; Rhizoma Atractylodis, Herba Menthae, Fructus Tribuli can wind and heat dispersing and end eye itching; Fructus Broussonetiae, Poria, Rhizoma Alismatis can invigorating spleen to remove dampness; Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription, and have anti-allergic effects, full side's dispelling wind makes eye bright, the dampness blood stasis dispelling, and conjunctival congestion and swelling pain, the secretions that causes for various diseases caused by exogenous pathogenic factor excess syndromes is many more, shed tears, ophthalmic pruritus etc. has splendid therapeutic effect.
Prescription of the present invention is at the ophthalmology excess syndrome, compatibility meticulously, and prescription is rigorous, uses clinical middle common Chinese medicine material, and is cheap, convenient and practical, and experimental results show that it has no side effect, and clinical effectiveness is remarkable.
The specific embodiment
Embodiment 1:
Present embodiment provides a kind of decoction for the treatment of oculopathy, and is formulated by the raw material of Chinese medicine medicine of following weight parts: Concha Haliotidis 13.5g, Semen Cassiae 13.5g, Radix Gentianae 8g, Cortex Phellodendri 8g, Rhizoma Anemarrhenae 11g, Radix Rehmanniae 11g, Rhizoma Alismatis 8g, Cortex Moutan 8g, Poria 8g, Herba Lycopi 8g, Flos Chrysanthemi 8g, Spica Prunellae 8g, Rhizoma Atractylodis 4.5g, Fructus Tribuli 8g, the sub-8g of Fructus Broussonetiae, Rhizoma Cyperi 8g, Fructus Leonuri 8g, Faeces Vespertilionis 8g, Radix Glycyrrhizae 4.5g.
Embodiment 2:
Present embodiment provides a kind of decoction for the treatment of oculopathy, and is formulated by the raw material of Chinese medicine medicine of following weight parts: Concha Haliotidis 17g, Semen Cassiae 17g, Radix Gentianae 12g, Cortex Phellodendri 12g, Rhizoma Anemarrhenae 13.5g, Radix Rehmanniae 13.5g, Rhizoma Alismatis 12g, Cortex Moutan 12g, Poria 12g, Herba Lycopi 12g, Flos Chrysanthemi 12g, Spica Prunellae 12g, Rhizoma Atractylodis 7.5g, Fructus Tribuli 12g, the sub-12g of Fructus Broussonetiae, Rhizoma Cyperi 12g, Fructus Leonuri 12g, Faeces Vespertilionis 12g, Radix Glycyrrhizae 7.5g.
Embodiment 3:
Present embodiment provides a kind of decoction for the treatment of oculopathy, and is formulated by the raw material of Chinese medicine medicine of following weight parts: Concha Haliotidis 15g, Semen Cassiae 15g, Radix Gentianae 10g, Cortex Phellodendri 10g, Rhizoma Anemarrhenae 12g, Radix Rehmanniae 12g, Rhizoma Alismatis 10g, Cortex Moutan 10g, Poria 10g, Herba Lycopi 10g, Flos Chrysanthemi 10g, Spica Prunellae 10g, Rhizoma Atractylodis 6g, Fructus Tribuli 10g, the sub-10g of Fructus Broussonetiae, Rhizoma Cyperi 10g, Fructus Leonuri 10g, Faeces Vespertilionis 10g, Radix Glycyrrhizae 6g.
It below is the explanation of the relevant performance of relevant drug toxicity experiment of the present invention and clinical observation, result of use.
The drug toxicity experiment
(1) test objective
Observe animal and use the toxic reaction that produces behind the present invention.
(2) test material
1, animal: select 90 of adult healthy SD rats for use, initial body weight 70-100g, male and female half and half, female rats all do not have pregnant, are provided by Disease Prevention Control Center, Hubei Prov.
2, medicine: the per weight dosage is by 10 times of calculating of clinical application amount (the clinical application amount is according to one one of Pharmacopoeia of the People's Republic of China version in 2010).I side: the decoction-Hayes for the treatment of oculopathy for the present invention soup that makes eye bright, wherein Concha Haliotidis 1.5, Semen Cassiae 1.5, Radix Gentianae 1.0, Cortex Phellodendri 1.0, the Rhizoma Anemarrhenae 1.2, the Radix Rehmanniae 1.2, Rhizoma Alismatis 1.0, Cortex Moutan 1.0, Poria 1.0, Herba Lycopi 1.0, Flos Chrysanthemi 1.0, Spica Prunellae 1.0, Rhizoma Atractylodis 0.6, Fructus Tribuli 1.0, Fructus Broussonetiae 1.0, Rhizoma Cyperi 1.0, Fructus Leonuri 1.0, Faeces Vespertilionis 1.0, Radix Glycyrrhizae 0.6, unit: g/kg.
3, instrument: Au 800 automatic clinical chemistry analyzers, Japanese OLYMPUS; AU-TOLAB blood cell automatic analyzer, Italian AMS; Untest 2200 Urine Analyzers, the Guilin City Medical Treatment Electronic Equipment Factory; Radiation plague enumerator.
(3) test method
1,90 SD rats are divided into 2 groups, 30 every group, male and female half and half, female rats all do not have pregnant.Experimental animal male and female sub-cage rearing, 5 in every cage, quantitative feeding (every cage 1000-1200g/ week), normal feedstuff is the experimental mouse full-valence pellet feed, freely drinks water.Experimental temperature (22 ± 2) ℃, humidity 60%-80%.The light and shade cycle of natural lighting and about 12h.
After the SD rat is bought, under this laboratory rearing condition, adapted to for 2 weeks, observe the general behavior performance.Measure the animal ingestion amount before the test.
2, grouping
2 groups are given normal saline, I side's filling stomach respectively.
3, medication
Decocting 2 times are distinguished by I side, and filtrate is considered to desired concn, raises the device gastric infusion with irritating, and every day 2 times, each volume is the 0.2ml/10g body weight, 26 weeks of successive administration.Matched group gives the normal saline with volume.Experimental animal is weighed weekly 1 time, adjusts dosage according to body weight change.24h after the 13rd all administrations puts to death 1/3 (male and female half and half), observes and detect every index for every group; Remaining continuation administration was observed to 26 weeks, and 24h after last 1 administration puts to death 1/3 (male and female half and half) again to observe and to detect every index for every group; 1/3 of remainder was carried out for 8 convalescent periods in week and is observed.
4, test item and time
4.1 the general situation of animal is observed in general inspection every day: as the mental status, reaction, behavioral activity, defecation situation, eyes and duct secretions, hair color, cleannes etc.Body weight change situation and food ration are measured weekly 1 time.
4.2 the 13rd, 26 weeks and the drug withdrawal recovery end of term (the 34th week) detects following index respectively after the hematological examination administration: red blood cell count(RBC) (RBC), content of hemoglobin (HGB), packed cell volume (HCT); Numeration of leukocyte (WBC), platelet count (PLT), lymphocyte comparative counting (LY), neutrophilic granulocyte comparative counting (NE), mononuclear cell comparative counting (Mon) and clotting time (CT).
4.3 the 13rd, 26 weeks and the drug withdrawal recovery end of term (the 34th week) detect following index respectively after the blood parameters inspection administration: Aspartic Acid transaminase (AST), alanine aminotransferase (ALT), alkali phosphatase (AST), gross protein (TP), albumin (ALB), total bilirubin (TB), blood glucose (GLU), blood urea nitrogen (BUN), creatinine (Crea), T-CHOL (TC), uric acid (UA), blood potassium (K+), blood sodium (Na+), blood calcium (Ca+) and B2M (blood β 2-MG, renal tubular function obstacle Sensitivity Index).
4.4 the 13rd, 26 weeks and the drug withdrawal recovery end of term (the 34th week) are respectively surveyed 1 time after routine urine examination,urine for routine and the administration of urine biochemical analysis.Animal metabolism cage list cage is raised and is collected 24h urine, overnight fasting before the test detects glucose (GLU), urine bilirubin (BIL), ketoboidies (KET), pH value, protein, urobilinogen (URO), nitrite (NIT), urinates occult blood (BLO), proportion and leukocyte (WBC); Quantitative determination of radioimmunoassay urine β 2-MG (renal tubular function obstacle sensitive indicator).
4.5 system's postmortem and histopathologic examination carry out macroscopy to each internal organs, the taking-up of organs such as heart, liver, spleen, lungs, kidney, adrenal gland, thymus, thyroid, pancreas, brain, uterus, ovary, testis, prostate is weighed, calculate organ coefficient (organ weights/body weight).
Above-mentioned internal organs and thymus, pancreas, spinal cord, hypophysis cerebri, optic nerve, lymph node, bladder, bone marrow (breastbone), stomach, duodenum, ileum, colon and rectum etc. are carried out histological examination with light microscopic.
(4) result
1, ordinary circumstance is observed:
2 groups of rats show no obvious abnormalities.
2, rat blood is learned the influence of index
The results are shown in Table 1 and table 2.After administration 13 week and 26 weeks, Chinese drug-treated group (namely using I side) the index of examining compare with matched group and all do not have significant difference.After drug withdrawal recovered for 8 weeks, each group every index of examining is compared with matched group did not all have significant difference.
Continuous 26 weeks of ig administration of table 1 and 8 convalescent periods in week are to the influence of rat blood cytology index
(n＝10，
)
Continuous 26 weeks of ig administration of table 2 and 8 convalescent periods in week are to the influence of rat blood cytology index
(n＝10，
)
3. to the influence of rat blood biochemical indicator
The results are shown in Table 3 and table 4.After 13 weeks of administration and 26 weeks, index that Chinese drug-treated group is examined is compared with matched group does not all have significant difference.After drug withdrawal recovered for 8 weeks, each group every index of examining is compared with matched group did not all have significant difference.
Continuous 26 weeks of ig administration of table 3 and 8 convalescent periods in week are to the influence of rat blood biochemical indexes
(n＝10，
)
Continuous 26 weeks of ig administration of table 4 and 8 convalescent periods in week are to the influence of rat blood biochemical indexes
(n＝10，
)
4, to the influence of rat urine
The results are shown in Table 5 and table 6.After 13 weeks of administration and 26 weeks, index that Chinese drug-treated group is examined is compared with matched group does not all have significant difference.After drug withdrawal recovered for 8 weeks, each group every index of examining is compared with matched group did not all have significant difference.
Continuous 26 weeks of ig administration of table 5 and 8 convalescent periods in week are to the influence of rat urine biochemical indicator
(n＝10，
)
Continuous 26 weeks of ig administration of table 6 and 8 convalescent periods in week are to the influence of rat urine biochemical indicator
(n＝10，
)
5. system's postmortem and histopathologic examination
Each treated animal does not all have macroscopic pathological change.Histological examination shows that respectively organizing each internal organs compares with matched group and there is no tangible pathological change.
6. brief summary
With Hayes make eye bright continuous 26 weeks of soup irritate stomaches after, rat blood is learned index, biochemical indicator, urine and pathology etc. has no effect, any toxic reaction does not appear.
Hayes of the present invention soup (specifically using the embodiment of the invention 3) the treatment conjunctival congestion redness 400 that makes eye bright
The summary of example clinical observation:
In JIUYUE, 2010-2012 year May, symptoms such as Hubei Affiliated Hospital of university of TCM use Hayes to make eye bright conjunctival congestion redness that external oculopathy oculopathy such as soup treatment catarrhal conjunctivitis, anterior uveitis, anaphylaxis conjunctivitis cause, ophthalmic pruritus, bite are totally 400 examples, and it has been carried out clinical observation, it is as follows now relevant clinical observation situation to be summed up report:
One, physical data
Above-mentioned period the court altogether the red and swollen patient of conjunctival congestion that causes of external oculopathy oculopathy such as diagnosis and treatment catarrhal conjunctivitis, anterior uveitis amount to 400 examples, get rid of the conjunctival congestion redness that is caused by wound, factor such as hemorrhage, be divided into treatment group and matched group at random.340 examples are organized in treatment, male 162 examples, and women 178 examples are the eyes morbidity; Age 13-65 year, 31 years old mean age, wherein 275 examples below 28 years old (80.8%); 1-4 days 266 examples of the morbidity course of disease, 74 examples more than 5 days; Diagnosis catarrhal conjunctivitis 113 examples, anaphylaxis conjunctivitis 91, anterior uveitis 32 examples, other 54 examples.Matched group 60 examples, male 27 examples, women 33 examples are the eyes morbidity; Age 14-64 year.32 years old mean age, wherein 48 examples below 28 years old (80.0%); The course of disease: 1-4 days 49 examples of falling ill, 11 examples more than 5 days; Diagnosis catarrhal conjunctivitis 25 examples, anaphylaxis conjunctivitis 21, anterior uveitis 6 examples, other 8 examples.
Two, Therapeutic Method
Matched group gives tobramycin dexamethasone eye drop eye drip, and every day 4 times, the levofloxacin gel for eye use is coated with eye, in every day, the evening 2 times; The treatment group is giving Hayes soup (embodiment of the invention 3) oral medication that makes eye bright with treatment of control group method basis.1 dose of every day, fry in shallow oil juice 200ml, divide clothes 2 times.2 groups was a course for the treatment of with 10 days all.
Three, evaluation criteria
Cure: subjective symptoms (itch, puckery, shed tears etc.) complete obiteration, the eyelid bulbar conjunctiva does not have hyperemia; Effectively: subjective symptoms is improved, and the hyperemia of eyelid bulbar conjunctiva alleviates; Invalid: treat after 10 days, symptom, sign all do not have obvious improvement.
Four, result
1.2 the group curative effect relatively: treatment is organized and is cured 307 examples, effective 30 examples, invalid 3 examples, cure rate 90.4%, total effective rate 99.0% in 340 examples; Cure 40 examples, effective 13 examples, invalid 7 examples, cure rate 66.7%, total effective rate 88.3% in matched group 60 examples.2 groups of curative effects relatively have significant difference.
2. treatment time relatively: treatment group average cure time 5 days, matched group average cure time are 9 days, and relatively there is significant difference 2 groups for the treatment of times.
3. follow-up observation: all cases were followed up a case by regular visits to 2-3 days, and no case was recurrence for the treatment group, matched group 16 example recurrences.2 groups relatively have significant difference.
Five, conclusion
Above-mentioned disease belongs to the traditional Chinese medical science " recurrence of disease at the same time next year disease " mostly, how because of zang-fu disharmony, ailment said due to cold or exposure invasion, on disturb key clearly, or hold because of on damp and hot, press from both sides ailment said due to cold or exposure again so that rheumatic fever three heresies are pented up, the stasis venation forms.Treatment should be based on wind and heat dispersing, dampness blood stasis dispelling.Hayes make eye bright Concha Haliotidis, Semen Cassiae, Radix Gentianae, Cortex Phellodendri, the detoxifcation of Radix Rehmanniae clearing away heat-fire in the soup prescription; The Radix Rehmanniae, Cortex Moutan, the blood stasis dispelling of Herba Lycopi's removing heat from blood and promoting blood circulation; Fructus Leonuri, Faeces Vespertilionis, Spica Prunellae, Fructus Lycii, Flos Chrysanthemi liver and kidney tonifying, liver heat removing and eyesight improving; Rhizoma Atractylodis, Herba Menthae, Fructus Tribuli wind and heat dispersing and end eye itching; Fructus Broussonetiae, Poria, Rhizoma Alismatis invigorating spleen to remove dampness; The Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription; All medicines also have anti-allergic effects.Full side has clearing away heat and expelling wind, dampness blood stasis dispelling, effect such as antipruritic makes eye bright.
The distinguishing feature of tcm treatment according to syndrome differentiation is with topical therapeutic and the close combination of wholistic therapy, and doctor's table effects a permanent cure and takes into account.Hormone has well-known untoward reaction, can occur hormone dependence, corticosteroid glaucoma etc. in the therapeutic process, and Chinese medicine then untoward reaction is little, but prolonged application.Discover that by this make eye bright symptoms such as conjunctival congestion redness that soup treatment external oculopathy oculopathy causes of Hayes are very necessary with feasible.This result of study shows that the Hayes soup that makes eye bright has and improves curative effect, shortens the course for the treatment of, reduces advantage such as recurrence, worth clinical application.
The Hayes red and swollen 160 example summaries of experience of soup treatment conjunctival congestion that make eye bright:
2011 to 2012, the inventor's outpatient service use Hayes to make eye bright conjunctival congestion redness that soup (specifically using the embodiment of the invention 3) treatment bacterial conjunctivitis and anaphylaxis conjunctivitis cause was totally 160 examples, existing with its sum up report as follows:
One, physical data
2011 to 2012, the red and swollen patient of conjunctival congestion that the common diagnosis and treatment bacterial conjunctivitis of the inventor's outpatient service, anaphylaxis conjunctivitis cause amounted to 160 examples, is the eyes morbidity; Male's 76 examples, women's 84 examples; Age 11-69 year, 32 years old mean age; Average 3 days of the morbidity course of disease; Diagnosing bacterial conjunctivitis 103 examples, anaphylaxis conjunctivitis 57 examples.
Two, Therapeutic Method
Give Hayes soup (embodiment of the invention 3) oral medication that makes eye bright.1 dose of every day, decocting 200ml divides clothes 2 times, takes 10 days.
Three, therapeutic evaluation
Cure: subjective symptoms (itch, puckery, shed tears etc.) complete obiteration, the eyelid bulbar conjunctiva does not have hyperemia;
Effectively: subjective symptoms is improved, and the hyperemia of eyelid bulbar conjunctiva alleviates;
Invalid: symptom, sign all do not have obvious improvement.
Four, therapeutic outcome
1. curative effect: cure 142 examples, effective 9 examples, invalid 9 examples, cure rate 88.7%, total effective rate 94.4% in 160 examples; The bacterial conjunctivitis patient cures 92 examples, effective 7 examples, invalid 4 examples, cure rate 89.3%, total effective rate 97.1%; The anaphylaxis conjunctivitis patient cures 50 examples, effective 2 examples, invalid 5 examples, cure rate 87.7%, total effective rate 91.2%.
2. treatment time: average cure time 6.4 days, bacterial conjunctivitis average cure time are 5.6 days, and the anaphylaxis conjunctivitis average cure time is 6.9 days.
Five, conclusion
The sickness rate of bacterial conjunctivitis and the anaphylaxis conjunctivitis modern medicine that rises year by year in recent years on these treatment of diseases is used eye drop local applications such as antibiotic and hormone more, effect still can, but the life-time service side effect is bigger.And Chinese medicine decoction action temperature of the present invention and, untoward reaction is little, but prolonged application.The inventor uses it and treats above-mentioned disease, and summary of experience as above proves that it has definite curative effect for the conjunctival congestion redness that bacterial conjunctivitis and anaphylaxis conjunctivitis cause, suitable clinical application.
Claims (3)
1. a decoction for the treatment of oculopathy is characterized in that by the raw material of Chinese medicine medicine of following weight parts formulated: Concha Haliotidis 13.5-17 part, Semen Cassiae 13.5-17 part, Radix Gentianae 8-12 part, Cortex Phellodendri 8-12 part, Rhizoma Anemarrhenae 11-13.5 part, Radix Rehmanniae 11-13.5 part, Rhizoma Alismatis 8-12 part, Cortex Moutan 8-12 part, Poria 8-12 part, Herba Lycopi 8-12 part, Flos Chrysanthemi 8-12 part, Spica Prunellae 8-12 part, Rhizoma Atractylodis 4.5-7.5 part, Fructus Tribuli 8-12 part, the sub-8-12 part of Fructus Broussonetiae, Rhizoma Cyperi 8-12 part, Fructus Leonuri 8-12 part, Faeces Vespertilionis 8-12 part, Radix Glycyrrhizae 4.5-7.5 part.
2. the decoction for the treatment of oculopathy as claimed in claim 1 is characterized in that by the raw material of Chinese medicine medicine of following weight parts formulated: Concha Haliotidis 14-16 part, Semen Cassiae 14-16 part, Radix Gentianae 8.5-11 part, Cortex Phellodendri 8.5-11 part, Rhizoma Anemarrhenae 11.5-13 part, Radix Rehmanniae 11.5-13 part, Rhizoma Alismatis 8.5-11 part, Cortex Moutan 8.5-11 part, Poria 8.5-11 part, Herba Lycopi 8.5-11 part, Flos Chrysanthemi 8.5-11 part, Spica Prunellae 8.5-11 part, Rhizoma Atractylodis 5-7 part, Fructus Tribuli 8.5-11 part, the sub-8.5-11 part of Fructus Broussonetiae, Rhizoma Cyperi 8.5-11 part, Fructus Leonuri 8.5-11 part, Faeces Vespertilionis 8.5-11 part, Radix Glycyrrhizae 5-7 part.
3. the decoction for the treatment of oculopathy as claimed in claim 1 is characterized in that by the raw material of Chinese medicine medicine of following weight parts formulated: 15 parts of Concha Haliotidis, 15 parts of Semen Cassiae, 10 parts of Radix Gentianaes, 10 parts of Cortex Phellodendris, 12 parts of the Rhizoma Anemarrhenaes, 12 parts in the Radix Rehmanniae, 10 parts of Rhizoma Alismatis, 10 parts of Cortex Moutans, 10 parts in Poria, 10 parts of Herba Lycopi, 10 parts of Flos Chrysanthemis, 10 parts of Spica Prunellaes, 6 parts of Rhizoma Atractylodis, 10 parts of Fructus Tribulis, 10 parts of Fructus Broussonetiae, 10 parts of Rhizoma Cyperis, 10 parts of Fructus Leonuris, 10 parts of Faeces Vespertilioniss, 6 parts in Radix Glycyrrhizae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102094199A CN102727729B (en) | 2012-06-25 | 2012-06-25 | Decoction for treating eye disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102094199A CN102727729B (en) | 2012-06-25 | 2012-06-25 | Decoction for treating eye disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102727729A CN102727729A (en) | 2012-10-17 |
| CN102727729B true CN102727729B (en) | 2013-09-04 |
Family
ID=46984493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012102094199A Expired - Fee Related CN102727729B (en) | 2012-06-25 | 2012-06-25 | Decoction for treating eye disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102727729B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103989876A (en) * | 2014-05-28 | 2014-08-20 | 高伦 | Traditional Chinese medicine for treating eye diseases |
| CN105963371A (en) * | 2016-06-16 | 2016-09-28 | 梁恩钜 | Eye medicine for treating ophthalmic diseases and preparing method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1205209A (en) * | 1997-07-14 | 1999-01-20 | 沈阳王朝医药保健品公司 | Eye clearing Chinese medicine placing in palpebra inferior and its prepn. method |
| CN101121012A (en) * | 2007-08-08 | 2008-02-13 | 李金山 | Traditional Chinese medicine for treating external oculopathy eye disease |
| CN102106977A (en) * | 2009-12-24 | 2011-06-29 | 孟繁英 | Externally-applied sturdy vision eyeshield liquid medicine for preventing and treating oculopathy |
| CN102631558A (en) * | 2012-04-25 | 2012-08-15 | 李敏 | Medicament for treating eye disease and preparation method of medicament |
-
2012
- 2012-06-25 CN CN2012102094199A patent/CN102727729B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1205209A (en) * | 1997-07-14 | 1999-01-20 | 沈阳王朝医药保健品公司 | Eye clearing Chinese medicine placing in palpebra inferior and its prepn. method |
| CN101121012A (en) * | 2007-08-08 | 2008-02-13 | 李金山 | Traditional Chinese medicine for treating external oculopathy eye disease |
| CN102106977A (en) * | 2009-12-24 | 2011-06-29 | 孟繁英 | Externally-applied sturdy vision eyeshield liquid medicine for preventing and treating oculopathy |
| CN102631558A (en) * | 2012-04-25 | 2012-08-15 | 李敏 | Medicament for treating eye disease and preparation method of medicament |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102727729A (en) | 2012-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103830577B (en) | A kind of medical composition and its use treating hepatobiliary calculus and urinary stone disease | |
| CN104645132B (en) | A kind of Chinese medicine composition that treating diabetic nephropathy, preparation method, Chinese medicine preparation and application | |
| CN101797335B (en) | Chinese medicinal composition for treating functional uterine bleeding | |
| CN102727729B (en) | Decoction for treating eye disease | |
| CN103212031A (en) | Traditional Chinese medicine composition for treating primary nephrotic syndrome and preparation method thereof | |
| CN111184792A (en) | Traditional Chinese medicine composition for treating knee osteoarthritis | |
| CN104147180B (en) | Pharmaceutical composition for the treatment of immunologic thrombocytopenic purpura and preparation method thereof | |
| CN114404538B (en) | Traditional Chinese medicine composition for treating gouty arthritis and application thereof | |
| CN102106993B (en) | Chinese medicinal composition for treating fatty liver and preparation method thereof | |
| CN102652774B (en) | Drug composition for treating leukopenia and hypoimmunity caused by chemoradiotherapy and preparation method and quality detection method | |
| CN104888157A (en) | Traditional Chinese medicine preparation for treating hysteromyoma and preparation method thereof | |
| CN102309705B (en) | Medicine for reducing serum uric acid, preparation method thereof and purpose thereof | |
| CN104474112A (en) | Traditional Chinese medicine for treating urinary calculus and preparation method of traditional Chinese medicine | |
| CN101138581B (en) | Traditional chinese medicine preparation for treating urinary system infection contamination and method of preparing the same | |
| CN104491101B (en) | Preparing method of traditional Chinese medicine preparation for treatment of chronic renal failure | |
| CN103191399A (en) | Traditional Chinese medicine composition for treating bronchial asthma in acute-outbreak period | |
| CN103417950A (en) | Traditional Chinese medicine composition for preventing and treating obese type 2 diabetes combined dyslipidemia | |
| CN103110756B (en) | Traditional Chinese medicine composition for treating renal hematuria | |
| CN102600424A (en) | Chinese herba preparation for treating nephropyelitis and preparation method of Chinese herba preparation | |
| CN105288501A (en) | Traditional Chinese medicine composition containing folium artemisiae argyi and treating obesity | |
| CN104491102B (en) | Colon positioning traditional Chinese medicine preparation for treating chronic kidney failure | |
| CN103735951B (en) | One treats psoriatic decoction | |
| CN105641633A (en) | Application of Chinese herbal medicine preparation in preparing medicine for treating obesity | |
| CN105288498A (en) | Method for preparing folium artemisiae argyi-contained traditional Chinese medicine preparation capable of treating obesity | |
| CN104958574A (en) | Traditional Chinese medicine preparation for treating cerebral concussion and preparation method of traditional Chinese medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130904 Termination date: 20180625 |